Table 2. Estimated direct medical costs (in ₦ as of March 2020).
| Disease events (annual) | Cost (₦) | Method/source |
|---|---|---|
| Acute myocardial infarction (AMI) | 402.411 | Microcosting |
| Non-AMI ischemic event | 1.173.994 | Microcosting |
| Stroke | 1.208.400 | Microcosting |
| Pneumonia/influenza | 61.249 | Microcosting |
| Moderate COPD (annual) | 232.556 | Microcosting |
| Lung cancer 1st year | 3.851.526 | Microcosting |
| Mouth cancer 1st year | 1.714.859 | Microcosting |
| Esophageal cancer 1st year | 1.264.945 | Microcosting |
| Stomach cancer 1st year | 1.266.866 | Microcosting |
| Pancreatic cancer 1st year | 1.918.056 | Microcosting |
| Kidney cancer 1st year | 1.525.267 | Microcosting |
| Laryngeal cancer 1st year | 1.792.030 | Microcosting |
| Leukemia 1st year | 2.650.265 | Microcosting |
| Bladder cancer 1st year | 1.241.534 | Microcosting |
| Cervical cancer 1st year | 2.446.750 | Microcosting |
| CHD follow-up (annual) | 193.106 | Indirect estimations |
| Stroke follow-up (annual) | 363.348 | Indirect estimations |
| Mild COPD (annual) | 86.782 | Indirect estimations |
| Severe COPD (annual) | 3.863.457 | Indirect estimations |
| Lung cancer 2nd year | 4.709.201 | Indirect estimations |
| Mouth cancer - 2nd year onwards | 1.277.677 | Indirect estimations |
| Esophageal cancer - 2nd year onwards | 936.001 | Indirect estimations |
| Stomach cancer - 2nd year onwards | 1.072.434 | Indirect estimations |
| Pancreatic cancer - 2nd year onwards | 1.540.811 | Indirect estimations |
| Kidney cancer - 2nd year onwards | 1.074.893 | Indirect estimations |
| Laryngeal cancer - 2nd year onwards | 705.926 | Indirect estimations |
| Leukemia - 2nd year onwards | 3.153.983 | Indirect estimations |
| Bladder cancer - 2nd year onwards | 977.246 | Indirect estimations |
| Cervical cancer - 2nd year onwards | 1.828.462 | Indirect estimations |
COPD: chronic obstructive pulmonary disease, CHD: coronary heart disease
* Exchange rate per dollar 1 U$D = 306.92 NGN.